The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 178 of the 179 references it cites were found in a registry or an index.
Abstract
Cholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA approved two anti-amyloid immunotherapies, lecanemab and donanemab, for “early-stage” AD, encompassing both stage 3 (MCI) and stage 4 (mild dementia).”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [18]
In the citing paper
“Degeneration of cholinergic neurons is known to significantly contribute to cognitive decline in AD patients [132] and has been studied in a variety of genetic AD mouse models.”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [132]
In the citing paper
“AChE contributes to acetylcholine depletion and may facilitate the formation of neurotoxic Aβ-AChE complexes38.”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [38]
In the citing paper
“Cholinergic deficit also alters the permeability of the blood brain barrier causing erroneous transportation of metabolites and hampering the removal of amyloid plaque, worsening the disease condition [8].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [8]
In the citing paper
“From this point of view, AD could be prevented or effectively treated by decreasing the production of Aβ and tau; preventing aggregation or misfolding of these proteins; neutralizing or removing the toxic aggregate or misfolded forms of these proteins; or a combination of these modalities.7”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [7]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Human Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Research works printed but not linked: 1
- Geula, 1994, Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease, 263
Cited by
Items 301–400 of 1,002
Crosstalk between bone and brain in Alzheimer's disease: Mechanisms, applications, and perspectives
Liu, Z., Liu, M., Xiong, Y., Wang, Y., & Bu, X. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13864 · Cited by 39
Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology
Mesulam, M.-M., Lalehzari, N., Rahmani, F., Ohm, D., Shahidehpour, R., Kim, G., Gefen, T., Weintraub, S., Bigio, E., & Geula, C. (2019) · Neurology · doi:10.1212/wnl.0000000000007247 · Cited by 39
Self-citationCholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson’s Disease
Iarkov, A., Mendoza, C., & Echeverría, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.665820 · Cited by 39
Current Progress on Central Cholinergic Receptors as Therapeutic Targets for Alzheimer's Disease
Nagori, K., Pradhan, M., Sharma, M. K., Ajazuddin, M., Badwaik, H. R., & Nakhate, K. T. (2024) · Current Alzheimer Research · doi:10.2174/0115672050306008240321034006 · Cited by 39
Carthamus tinctorius L.: A natural neuroprotective source for anti-Alzheimer's disease drugs
Liang, Y., & Wang, L. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115656 · Cited by 39
Approved drugs and natural products at clinical stages for treating Alzheimer’s disease
Ma, Y., Liu, S., Zhou, Q., Zhong-hua, L., ZHANG, Z., & Yu, B. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60606-0 · Cited by 39
Zong, B., Yu, F., Zhang, X., Zhao, W., Sun, P., Li, S., & Li, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.869507 · Cited by 39
Cholinergic dysfunction in COVID-19: frantic search and hoping for the best
Nadwa, E. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Elekhnawy, E., Albogami, S. M., Alorabi, M., Batiha, G. E., & WAARD, M. M. D. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02346-9 · Cited by 39
Role of aluminum exposure on Alzheimer’s disease and related glycogen synthase kinase pathway
Sanajou, S., Erkekoğlu, P., Şahin, G., & Baydar, T. (2022) · Drug and Chemical Toxicology · doi:10.1080/01480545.2022.2065291 · Cited by 39
Salvo, C. D., D’Antongiovanni, V., Benvenuti, L., d’Amati, A., Ippolito, C., Segnani, C., Pierucci, C., Bellini, G., Annese, T., Virgintino, D., et al. (2024) · Food & Function · doi:10.1039/d4fo02075h · Cited by 38
Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 38
Advances in Drug Therapy for Alzheimer’s Disease
Zhu, C.-C., Fu, S., Chen, Y., Li, L., Mao, R., Wang, J., Liu, R., Liu, Y., & Wang, X. (2020) · Current Medical Science · doi:10.1007/s11596-020-2281-2 · Cited by 38
Chen, H., Mi, J., Li, S., Liu, Z., Yang, J. L., Chen, R., Wang, Y., Ban, Y., Zhou, Y. M., Dong, W., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2169682 · Cited by 38
Zhu, C., Han, J., Liang, F., Zhu, M., Zhang, G., James, T. D., & Wang, Z. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216002 · Cited by 38
Barbosa, M., Valentão, P., & Andrade, P. B. (2020) · Marine Drugs · doi:10.3390/md18120654 · Cited by 38
The effect of maslinic acid on cognitive dysfunction induced by cholinergic blockade in mice
Bae, H. J., Kim, J., Kim, J., Goo, N., Cai, M., Cho, K., Jung, S. Y., Kwon, H., Kim, D. H., Jang, D. S., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15042 · Cited by 38
Peng, X., Chen, L., Wang, Z., He, Y., Ruganzu, J. B., Guo, H., Zhang, X., Ji, S., Zheng, L., & Yang, W. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174772 · Cited by 38
Slow-binding inhibitors of acetylcholinesterase of medical interest
Lushchekina, S. V., & Masson, P. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108236 · Cited by 38
Synthesis of piperine analogues as AChE and BChE inhibitors for the treatment of Alzheimer's disease
Jaipea, S., Saehlim, N., Sutcharitruk, W., Athipornchai, A., Ingkaninan, K., & Saeeng, R. (2023) · Phytochemistry Letters · doi:10.1016/j.phytol.2023.01.004 · Cited by 38
C/EBPβ/AEP Signaling Drives Alzheimer’s Disease Pathogenesis
Xiong, J., Zhang, Z., & Ye, K. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01025-w · Cited by 37
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 38
Alzheimer’s Disease Treatment: The Search for a Breakthrough
Reiss, A. B., Muhieddine, D., Jacob, B., Mesbah, M., Pinkhasov, A., Gomolin, I. H., Stecker, M. M., Wısnıewskı, T., & Leon, J. D. (2023) · Medicina · doi:10.3390/medicina59061084 · Cited by 37
Solomon, E. A., Davis, K. L., Hovde, B. T., Micheva‐Viteva, S., Harris, J. F., Twary, S. N., & Iyer, R. S. (2021) · BMC Molecular and Cell Biology · doi:10.1186/s12860-021-00343-z · Cited by 37
Autonomic Imbalance and Risk of Dementia and Stroke: The Framingham Study
Weinstein, G., Davis‐Plourde, K. L., Beiser, A., & Seshadri, S. S. (2021) · Stroke · doi:10.1161/strokeaha.120.030601 · Cited by 38
Kohelová, E., Peřinová, R., Maafi, N., Korábečný, J., Hulcová, D., Maříková, J., Kučera, T., Martínez‐González, L., Hrabinová, M., Vorčáková, K., et al. (2019) · Molecules · doi:10.3390/molecules24071307 · Cited by 37
Hu, W., Li, Z., Wang, W., Song, M., Dong, R., Zhou, Y., Li, Y., & Wang, D. (2021) · Food & Function · doi:10.1039/d1fo01963e · Cited by 37
The Roles of Tetramethylpyrazine During Neurodegenerative Disease
Meng, Z., Chen, H., & Meng, S. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00398-y · Cited by 37
The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer’s Cholinergic Atrophy
Carmo, S. D., Kannel, B., & Cuello, A. C. (2021) · Cells · doi:10.3390/cells11010016 · Cited by 37
Self-citationWoon, C. K., Hui, W. K., Abas, R., Haron, M. H., Das, S., & Lin, T. S. (2021) · Current Neuropharmacology · doi:10.2174/1570159x20666211217163540 · Cited by 37
Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review
Pozzi, F. E., Conti, E., Appollonio, I., Ferrarese, C., & Tremolizzo, L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.998224 · Cited by 36
Dong, Q., Li, Z., Zhang, Q., Hu, Y., Liang, H., & Xiong, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.924429 · Cited by 36
Status of Metabolomic Measurement for Insights in Alzheimer’s Disease Progression—What Is Missing?
Yin, C., Harms, A. C., Hankemeier, T., Kindt, A. S. D., & de Lange, E. C. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054960 · Cited by 36
Yang, W., Shi, Y., Zhang, Y., Yang, Y., Du, Y., Yang, Z., Wang, X., Lei, T., Xu, Y., Chen, Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c09449 · Cited by 36
Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors
Meden, A., Knez, D., Malikowska‐Racia, N., Brazzolotto, X., Nachon, F., Svete, J., Sałat, K., Grošelj, U., & Gobec, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112766 · Cited by 36
Unlocking the Therapeutic Potential of Natural Products for Alzheimer’s Disease
Li, Z., Zhang, Z., & Yu, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03049 · Cited by 36
Ongoing Research on the Role of Gintonin in the Management of Neurodegenerative Disorders
Ikram, M. A., Ullah, R., Khan, A., & Kim, M. O. (2020) · Cells · doi:10.3390/cells9061464 · Cited by 36
Verapamil and Alzheimer’s Disease: Past, Present, and Future
Popović, N., Morales-Delgado, N., Mena, D. V., Alonso, A., Martínez, M. P., Bleda, M. C., & Popović, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00562 · Cited by 36
Cappon, D., Fox, R., den Boer, T., Yu, W., LaGanke, N., Cattaneo, G., Perellón‐Alfonso, R., Bartrés‐Faz, D., Manor, B. D., & Pascual‐Leone, Á. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1168673 · Cited by 36
Wang, S., Zhao, Q., Li, G., Wang, M., Liu, H., Yu, X., Chen, J., Li, P., Dong, L., Zhou, G., et al. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112959 · Cited by 36
Yang, X., Wang, R., Zhou, H., Wang, L., Wang, R., Li, H., Tan, B., Wu, Q., Xu, X., Cui, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.751028 · Cited by 43
Antonioni, A., Martorana, A., Santarnecchi, E., Hampel, H. J., & Koch, G. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70337 · Cited by 35
Self-citationAlzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies
Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I. A., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 35
Li, X., Ding, Q., Wan, X., Wu, Q., Ye, S., & Lou, Y. (2025) · Behavioral and Brain Functions · doi:10.1186/s12993-024-00265-8 · Cited by 35
Debnath, I., Ghosh, S., Jha, S. K., Bhunia, S., Nayak, A., Basak, S., Nandi, S., & Bhattacharjee, S. (2025) · BIO Integration · doi:10.15212/bioi-2025-0073 · Cited by 35
EAAT2 as a therapeutic research target in Alzheimer's disease: A systematic review
Wood, O. W. G., Yeung, J. H. Y., Faull, R. L. M., & Kwakowsky, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.952096 · Cited by 35
Nepovimová, E., Svobodová, L., Doležal, R., Hepnarová, V., Junova, L., Jun, D., Korábečný, J., Kucera, T., Gažová, Z., Motykova, K., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104596 · Cited by 35
Humanin and Alzheimer's disease: The beginning of a new field
Niikura, T. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.130024 · Cited by 35
Oh, Y., Do, H. T. T., Kim, S.-Y., Kim, Y., Chin, Y., & Cho, J. (2020) · Antioxidants · doi:10.3390/antiox10010034 · Cited by 35
Choline and phosphatidylcholine may maintain cognitive performance by multiple mechanisms
Shea, T. B. (2019) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz244 · Cited by 35
Lang, F. M., Mo, Y., Sabbagh, M., Solomon, P., Boada, M., Jones, R. W., Frisoni, G. B., Grimmer, T., Dubois, B., Harnett, M., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12136 · Cited by 34
“Patients were excluded if they (1) showed evidence of dementia not related toAD; (2) had ahistory of significant neurological or psychiatric illness; (3) had a history of negative amyloid positron emission tomography (PET) scan (n.”
InfluentialZhou, S., Liu, J., Sun, Y., Xu, P., Liu, J. L., Sun, S., Zhu, B., & Wu, H. (2023) · Food & Function · doi:10.1039/d2fo03874a · Cited by 34
The role of synaptic biomarkers in the spectrum of neurodegenerative diseases
Mazzucchi, S., Palermo, G., Campese, N., Galgani, A., Vecchia, A. D., Vergallo, A., Siciliano, G., Ceravolo, R., Hampel, H. J., & Baldacci, F. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1831388 · Cited by 35
Self-citationTractography of the external capsule and cognition: A diffusion MRI study of cholinergic fibers
Nolze-Charron, G., Rouleau, R. D., Houde, J., Dumont, M., Castellano, C., Cunnane, S. C., Lorrain, D., Fülöp, T., Descoteaux, M., & Bocti, C. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110792 · Cited by 34
Xu, X., Wang, T., Li, W., Li, H., Xu, B., Zhang, M., Yue, L., Wang, P., & Xiao, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.688113 · Cited by 34
Roles and Mechanisms of the Protein Quality Control System in Alzheimer’s Disease
Liu, Y., Ding, R., Xu, Z., Xue, Y., Zhang, D., Zhang, Y., Li, W., & Li, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010345 · Cited by 34
Topkara, K. Ç., Kılınç, E., Çetinkaya, A., Şaylan, A., & Demír, Ş. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15565 · Cited by 34
Ye, Q., Gast, G., Su, X., Saito, T., Saido, T. C., Holmes, T. C., & Xu, X. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105820 · Cited by 34
An examination of three prescribing cascades in a cohort of older adults with dementia
Trenaman, S. C., Bowles, S. K., Kirkland, S., & Andrew, M. K. (2021) · BMC Geriatrics · doi:10.1186/s12877-021-02246-2 · Cited by 34
Alhawarri, M. B., Dianita, R., Rawa, M. S. A., Nogawa, T., & Wahab, H. A. (2023) · Plants · doi:10.3390/plants12020344 · Cited by 33
Chu, K.-T., Lei, W.-C., Wu, M., Fuh, J., Wang, S., French, I. T., Chang, W.-S., Chang, C., Huang, N. E., Liang, W., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1195424 · Cited by 33
Yan, Y., Aierken, A., Wang, C., Song, D. F., Ni, J., Wang, Z., Quan, Z., & Qing, H. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.009 · Cited by 33
The microbial metabolite trimethylamine N-oxide and the kidney diseases
Su, J. Q., Wu, X., Wang, Q., Xie, B.-Y., Xiao, C.-Y., Su, H.-Y., Tang, J., & Yao, C. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1488264 · Cited by 33
Cholinergic neurodegeneration in Alzheimer disease mouse models
Shekari, A., & Fahnestock, M. L. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819973-2.00013-7 · Cited by 34
Exploring Alzheimer's disease treatment: Established therapies and novel strategies for future care
Soni, U., Singh, K., Jain, D., & Pujari, R. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177520 · Cited by 33
A novel process driving Alzheimer's disease validated in a mouse model: Therapeutic potential
Greenfield, S. A., Cole, G. M., Coen, C. W., Frautschy, S. A., Singh, R. P., Mekkittikul, M., Garcia‐Ratés, S., Morrill, P. R., Hollings, O., Passmore, M., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12274 · Cited by 33
Yamini, P., Ray, R. S., Yadav, S., Dhaliwal, J., Yadav, M., Kondepudi, K. K., & Chopra, K. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173402 · Cited by 33
MacDougall, G., Brown, L. Y., Kantor, B., & Chiba‐Falek, O. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.001 · Cited by 33
SAR studies of quinoline and derivatives as potential treatments for Alzheimer’s disease
Li, Z., Yin, L., Zhao, D., Jin, L., Sun, Y.-J., & Tan, C. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2022.104502 · Cited by 33
Lee, C.-Y., Chan, L., Hu, C., Hong, C., & Chen, J. (2024) · Aging · doi:10.18632/aging.205788 · Cited by 33
Li, Q., Rubin, L., Silva, M., Li, S., Yang, C., Lazarovici, P., & Zheng, W. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3777021 · Cited by 33
Jarzębowski, P., Tang, C. S., Paulsen, O., & Hay, Y. A. (2021) · eLife · doi:10.7554/elife.65998 · Cited by 33
Yan, C., Yang, S., Shao, S., Zu, R., Hao, L., Chen, Y., Zhou, Y., Ying, X., Xiang, S., Zhang, P., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117915 · Cited by 33
Pharmacological evaluation of bromelain in mouse model of Alzheimer’s disease
Kumar, R., Kumar, R., Sharma, N., Khurana, N., Singh, S. K., Satija, S., Mehta, M., & Vyas, M. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.02.009 · Cited by 33
Switching On/Off Amyloid Plaque Formation in Transgenic Animal Models of Alzheimer’s Disease
Kozin, S. A., Kechko, O. I., Adzhubei, A. A., Makarov, A. А., & Mitkevich, V. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010072 · Cited by 32
Merde, İ. B., Özdemir, Z., Uslu, H., Özçelik, A. B., Şenol, F. S., Orhan, İ. E., & Uysal, M. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666191010154444 · Cited by 32
Tok, F., Sağlık, B. N., Özkay, Y., Kaplancıklı, Z. A., & Koçyiğit‐Kaymakçıoğlu, B. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133441 · Cited by 32
Lai, Z., Ke, L. W., & Zhao, W. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1647967 · Cited by 32
Wang, Y., Zhang, H., Liu, D., Li, X., Long, L., Peng, Y., Qi, F., Wang, Y., Jiang, W., & Wang, Z. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105993 · Cited by 32
Liu, G., Yu, Q., Zhu, H., Tan, B., Yu, H., Li, X., Lu, Y., & Li, H. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04948-9 · Cited by 32
Multi-Target-Directed Cinnamic Acid Hybrids Targeting Alzheimer’s Disease
Drakontaeidi, A., & Pontiki, E. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010582 · Cited by 32
Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer’s disease
Neha, N., & Parvez, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101815 · Cited by 32
Deng, Y., Kuo, K., Wu, B., Ou, Y., Liu, Y., Zhang, Y.-R., Huang, S., Chen, S.-D., Yu, C., Zhang, R., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01088-3 · Cited by 32
Benwood, C., Walters-Shumka, J. P., Scheck, K., & Willerth, S. M. (2023) · Bioelectronic Medicine · doi:10.1186/s42234-023-00112-7 · Cited by 32
Pharmacological Activities and Molecular Mechanisms of Sinapic Acid in Neurological Disorders
Farzan, M., Abedi, B., Bhia, I., Madanipour, A., Farzan, M., Bhia, M., Aghaei, A., Kheirollahi, I., Motallebi, M., Amini-Khoei, H., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00349 · Cited by 32
Effect of a dual orexin receptor antagonist on Alzheimer's disease: Sleep disorders and cognition
Zhou, M., & Tang, S. H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.984227 · Cited by 32
Celep, İ. K., Zengin, G., Sinan, K. I., Ak, G., Elbasan, F., Yıldıztugay, E., Maggi, F., Caprioli, G., Angeloni, S., Jugreet, S., et al. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112330 · Cited by 32
Liao, Y., Hu, X., Pan, J., & Zhang, G. (2022) · Foods · doi:10.3390/foods11020168 · Cited by 32
Özçelik, A. B., Özdemir, Z., Sarı, S., Utku, S., & Uysal, M. (2019) · Pharmacological Reports · doi:10.1016/j.pharep.2019.07.006 · Cited by 32
Nanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
Cholinergic nucleus 4 atrophy and gait impairment in Parkinson’s disease
Dalrymple, W. A., Huss, D., Blair, J. C., Flanigan, J. L., Patrie, J. T., Sperling, S. A., Shah, B., Harrison, M. B., Druzgal, T. J., & Barrett, M. J. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10111-2 · Cited by 31
Farkas, S., Szabó, A., Török, B., Sólyomvári, C., Fazekas, C. L., Bánrévi, K., Correia, P., Chaves, T., & Zelena, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.985424 · Cited by 31
Yao, Q., Jiang, K., Lin, F., Zhu, T., Khan, N. H., & Jiang, E. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s400527 · Cited by 31
Pasieka, A., Panek, D., Jończyk, J., Godyń, J., Szałaj, N., Latacz, G., Tabor, J., Mezeiová, E., Chantegreil, F., Dias, J., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113397 · Cited by 31
DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease
de Souza, M. M., Cenci, A. R., Teixeira, K. F., Machado, V., Schülerb, M. C. G. M., Gonçalves, A. E., Dalmagro, A. P., Cazarin, C. A., Ferreira, L. L. G., de Oliveira, A. S., et al. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220620162018 · Cited by 33
Andrade-Guerrero, J., Rodríguez-Arellano, P., Barron-Leon, N., Orta‐Salazar, E., Ledesma-Alonso, C., Díaz-Cintra, S. Y., & Soto-Rojas, L. O. (2023) · Cells · doi:10.3390/cells12212531 · Cited by 31
Inflammatory neuropsychiatric disorders and COVID-19 neuroinflammation
Tang, S. W., Helmeste, D. M., & Leonard, B. E. (2021) · Acta Neuropsychiatrica · doi:10.1017/neu.2021.13 · Cited by 31
Koppelmans, V., Ruitenberg, M. F. L., Schaefer, S. Y., King, J. B., Hoffman, J. M., Mejia, A. F., Taşdizen, T., & Duff, K. M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221297 · Cited by 31
Wichur, T., Godyń, J., Góral, I., Latacz, G., Bucki, A., Siwek, A., Głuch‐Lutwin, M., Mordyl, B., Śniecikowska, J., Walczak, M., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113792 · Cited by 31
Tang, J., Yousaf, M., Wu, Y., Li, Q., Xu, Y., & Liu, D. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127553 · Cited by 31
Zou, D., Huang, X., Lan, Y., Pan, M., Xie, J., Huang, Q., Zeng, J., Zou, C., Pei, Z., Zou, C., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107098 · Cited by 31
Metadata
- Authors
- Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Northwestern University (US)
- McGill University (CA)
- Indiana University School of Medicine (US)
- University Hospital of Geneva (CH)
- Saint Louis University (US)
- Prevent Alzheimer’s Disease 2020 (US)
- University of Rhode Island (US)
- Corresponding author
- Hampel, Harald
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-29
- Volume
- 141
- Issue
- 7
- Pages
- 1917-1933
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6022632
- OpenAlex
- W2805257646
- Cited by
- 1,918
- References
- 179
- Citations by year
- 2026: 245 · 2025: 298 · 2024: 298 · 2023: 328 · 2022: 300 · 2021: 228 · 2020: 130 · 2019: 65 · 2018: 21
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- AXA Research Fund
- ‘Fondation pour la Recherche sur Alzheimer’, Paris, France. Ce travail a bénéficié d'une aide de l’Etat ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- Canadian Institutes of Health Research
- National Research Council
- Alzheimer Society of Canada
- Rotary Club Livorno ‘Mascagni’/The Rotary Foundation (GG1758249)
- ADC (AG013854)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic system, cholinergic hypothesis, cholinesterase inhibitors, acetylcholine, cholinergic denervation, neurofibrillary degeneration, amyloid plaques, cognitive decline, cholinergic drugs, combination therapy
- MeSH terms
- Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Humans, Amyloid beta-Peptides, Neurofibrillary Tangles, Cholinergic Agents, Cholinergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.